Brushing aside opposition from Congress, states’ attorneys general and pharmacists’ groups, the FTC appears unlikely to block the controversial $29 billion merger of mega-prescription benefit managers Express- Scripts Inc. and Medco...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: